brain/
sourcestock-market

Autoresearch: FDA rare-disease right-shift (AGIO / REPL / Capricor / DYN) — 19 Sep 2026 status

Status check on Agios mitapivat SCD PDUFA (still 1 Nov 2026, not approved), REPL/Capricor Jul 30 ADCOM outcomes, Dyne Jan 2027 PDUFA, no second missed-endpoint approval, no step-1 refile-CRL falsifier, CRL transparency partially resumed.

Source

Autoresearch: FDA rare-disease right-shift (AGIO / REPL / Capricor / DYN) — 19 Sep 2026 status

Generated by /autoresearch on 2026-09-19. Synthesized across 3 rounds from official FDA, ClinicalTrials.gov, issuer IR / SEC exhibits, and openFDA. Grokipedia/encyclopedia skipped per brief. Treat as raw material — review before promoting. Do not re-rate AGIO/REPL/QURE/SRPT/RGNX/DYN. Do not file "approved despite missed VOC." Context: vault/projects/stock-market (fda-right-shift-to-rare-disease-refile-rerate)

Summary

As of 19 September 2026 the Agios mitapivat sickle-cell sNDA is still live: Priority Review, PDUFA 1 November 2026, not approved, no company-paper ADCOM, REIGNITE still RECRUITING. That is acceptance, not approval. The July 30 Diamantes-era ADCOMs split: Replimune RP1/TUDRIQEV got a 10–3 favorable CTGTAC vote then accelerated approval on 6 August 2026 (melanoma refile after two CRLs — oncology, not a missed-endpoint rare-disease approval). Capricor deramiocel got a 9–3 vote against cardiomyopathy effectiveness, then a major-amendment deferral to 22 November 2026 — neither approve nor a new CRL. Dyne’s z-rostudirsen PDUFA is 21 January 2027, not late-January 2026; not decided. There is no second missed-endpoint rare-disease APPROVAL. Ultragenyx FAYUVI (UX111) was approved 17 September 2026 after a CMC CRL, which is a rare-disease refile approval but not the missed-endpoint test. No high-profile refile CRL has fired the step-1 falsifier. FDA CRL transparency was paused after the April 2026 Covington petition and partially resumed (openFDA last updated 13 August 2026; letters dated through 7 August 2026). Honesty: stay partial on steps 1–2; stay open on step 3.

Priors check

  • Confirmed — Agios sNDA still Priority Review / PDUFA 1 Nov 2026 / not approved; REIGNITE still recruiting; "no ADCOM" still absent from company PRs and the Q2 2026 earnings exhibit; step 1 is still acceptance, not approval (Agios 7 Jul 2026 GNW; Agios Q2 2026 8-K Ex. 99.1; FDA OOPD mitapivat SCD; NCT07656415).
  • Refined — Jul 30 ADCOMs are no longer "upcoming": REPL approved; Capricor deferred after a negative vote (REPL 8-K Ex. 99.1, 30 Jul 2026; FDA TUDRIQEV approval letter, 6 Aug 2026; Capricor 30 Jul 2026 PR; Capricor 24 Aug 2026 PR).
  • Contradicted (calendar, not thesis) — DYN is not a late-January 2026 PDUFA. FDA accepted the BLA on 20 July 2026 with PDUFA 21 January 2027; undecided (Dyne 8-K, 20 Jul 2026). Calibration-worthy as a date error in the 24 Jul podcast prior, not as a decision.
  • Contradicted (information-edge prior) — "No CRLs released since April" is stale. Publication paused after the Covington petition, then resumed; openFDA shows 458 records, last_updated 2026-08-13, newest letter 7 Aug 2026 (openFDA CRL API; Regulations.gov FDA-2026-P-4369).
  • Untested / still open — A second missed-endpoint rare-disease APPROVAL that would move step 1; a high-profile refile CRL that would fire the step-1 falsifier; whether Diamantes-era decisions are reliably lenient vs erratic (REPL yes / Capricor no).

Surprising finding (do not re-rate; do not file as missed-VOC approval): FDA granted TUDRIQEV accelerated approval over a primary clinical-review-team non-recommend, citing "regulatory flexibility" after a 10–3 ADCOM (FDA SBRA, 6 Aug 2026).

Findings

Agios mitapivat SCD sNDA — PDUFA still 1 Nov 2026; Priority Review; not approved; no company ADCOM; REIGNITE recruiting

FDA accepted the mitapivat sickle-cell sNDA with Priority Review on 7 July 2026. The PDUFA goal date is November 1, 2026, under the accelerated-approval pathway (Agios / GlobeNewswire, 7 Jul 2026; issuer URL of record: investor.agios.com July 7 release — IR HTML 403'd this pass; text recovered from the GNW reprint).

The same date is restated in the 30 July 2026 Q2 earnings exhibit, with first-patient-dosed language for REIGNITE and zero ADCOM words (Agios 8-K Ex. 99.1, 30 Jul 2026). Agios EDGAR has no later 8-K that changes the PDUFA (latest 10-Q / earnings 8-K 30 Jul 2026; submissions JSON through 6 Aug 2026 shows no subsequent SCD-action 8-K) (data.sec.gov submissions CIK 0001439222).

FDA's orphan-drug listing still says mitapivat is designated for sickle cell and Not FDA Approved for Orphan Indication (FDA OOPD, cfgridkey 781120). File as mitapivat sNDA, not PYRUKYND-branded SCD. Do not file "approved despite missed VOC."

The missed SCPC co-primary remains the 19 Nov 2025 RISE UP topline: hemoglobin response met (40.6% vs 2.9%, p<0.0001); annualized SCPC 2.62 vs 3.05, 2-sided p=0.1213 (Agios RISE UP PR, 19 Nov 2025).

ADCOM: Schmidt's "no ADCOM" is still a podcast prior. It is not in the 7 Jul acceptance PR, the 30 Jul Q2 exhibit, or any later Agios 8-K reviewed here. FDA advisory-committee calendar HTML paths 404'd on fetch; search of the live calendar did not surface a mitapivat / Agios / PYRUKYND SCD meeting (unrelated July compounding and November microbiology-device panels only). Leave "no ADCOM" unverified from company paper and unlisted on the calendar as of this pass — absence of a listing is not a company confirmation.

REIGNITE: ClinicalTrials.gov API, status verified 2026-08, last posted 4 Aug 2026: RECRUITING. NCT07656415, Agios AG348-C-030, Phase 3, n=159 estimated, start 21 Jul 2026 (actual), primary completion Aug 2029 (est.). Three US sites listed recruiting (Indianapolis, Grand Rapids, Flowood). Version holder 18 Sep 2026 (ClinicalTrials.gov NCT07656415; API JSON).

Replimune RP1 / TUDRIQEV — Jul 30 ADCOM 10–3, then accelerated approval 6 Aug 2026

This was the first very public Diamantes-era decision on the July 30 docket. CTGTAC voted 10 to 3 that IGNYTE efficacy results are "evaluable and clinically meaningful." Class 1 resubmission action date was 2 Aug 2026 (REPL 8-K, 30 Jul 2026; Ex. 99.1).

FDA granted accelerated approval on 6 August 2026 for TUDRIQEV (vusolimogene oderparepvec-wtpg), formerly RP1, plus nivolumab in unresectable advanced cutaneous melanoma after PD-1 progression. The approval letter treats the 2 Jun 2026 amendment as a complete response to the 10 April 2026 action letter (second CRL). Confirmatory IGNYTE-3 (NCT06264180) is required; OS primary; trial completion Sep 2030 / final report Mar 2031 (FDA approval letter, 6 Aug 2026; REPL Ex. 99.1, 6 Aug 2026).

The SBRA records a live split: CTGTAC 10–3 favorable; "The primary clinical review team does not recommend approval" because CRL deficiencies were not addressed; OTP/OCE nonetheless recommends accelerated approval, "exercising the regulatory flexibility afforded under the Accelerated Approval pathway" (FDA SBRA, 6 Aug 2026).

How to file: this is a high-profile oncology refile APPROVAL after two CRLs + ADCOM, and a Diamantes-era litmus that went approve. It is not a missed-endpoint rare-disease approval and not "approved despite missed VOC." Do not re-rate REPL.

Capricor deramiocel — Jul 29–30 ADCOM 9–3 against; then deferral to 22 Nov 2026 (not approve, not a new CRL)

CTGTAC voted that available evidence did not support effectiveness of deramiocel for DMD cardiomyopathy — 3 for, 9 against, 0 abstain. Non-binding. The voting question was narrower than Capricor's proposed label; no overall benefit-risk vote. Company said upper-limb (HOPE-3 PUL 2.0) discussion was "directionally supportive." Then-PDUFA was 22 Aug 2026 (Capricor PR, 30 Jul 2026).

On 24 August 2026 FDA extended PDUFA from 22 August 2026 to 22 November 2026 after accepting a major amendment (24-month HOPE-3 OLE + robustness analyses; refined proposed indication = upper limb function). CBER cited significant unmet need in DMD. Product remains investigational / not approved (Capricor PR, 24 Aug 2026). No subsequent approve/CRL PR found through 19 Sep 2026.

How to file: first public Diamantes-era rare-disease ADCOM on this docket went against the cardiomyopathy claim, then defer rather than CRL or approve. That is erratic / not uniformly lenient, not a step-1 confirm and not a clean step-1 falsifier.

Dyne (DYN) — not a late-January 2026 PDUFA; date is 21 Jan 2027; not decided

The 24 Jul podcast "late-January PDUFA" prior is a calendar error. Dyne announced FDA acceptance on 20 July 2026: Priority Review; PDUFA January 21, 2027; launch assumed Q1 2027 if approved on that timeline (Dyne 8-K, 20 Jul 2026; issuer URL of record: investors.dyne-tx.com July 20 release — IR HTML 403'd; text from the 8-K). Subsequent DYN 8-Ks (22 Jul; 29 Jul earnings/10-Q; submissions through 8 Sep) do not record an approval or CRL. Not decided. Do not re-rate DYN.

No second missed-endpoint rare-disease APPROVAL

Step 1's open test was a second rare-disease APPROVAL after a missed primary/co-primary, not another acceptance and not a CMC refile.

  • Agios SCD: still not approved (see above).
  • REPL TUDRIQEV: approved, but melanoma / oncolytic, after CRLs on whether IGNYTE was adequate-and-well-controlled — not a missed rare-disease endpoint.
  • Ultragenyx FAYUVI (UX111 / rebisufligene etisparvovec-hopf): FDA approved 17 September 2026 — first therapy for pediatric MPS IIIA / Sanfilippo A; standard full approval for neurologic manifestations in pediatric patients with preserved neurodevelopmental function. The 17 Sep letter acknowledges the 20 Mar 2026 amendment as a complete response to the 7 July 2025 action letter, which Ultragenyx described as CMC / inspection, not a missed efficacy endpoint (FDA approval letter, 17 Sep 2026; Ultragenyx Jul 2025 CRL PR; Ultragenyx 17 Sep 2026 GNW reprint). Rare-disease refile approval, yes. Missed-endpoint approval, no.
  • Capricor: not approved.

Step 1 stays partial. Do not graduate on FAYUVI or TUDRIQEV.

Step-1 falsifier (high-profile refile CRL) — not fired

No post-April high-profile rare-disease refile has drawn a new efficacy CRL that would show Agios acceptance was program-specific:

  • Capricor is a negative ADCOM + major-amendment deferral, not a CRL.
  • Disc Medicine bitopertin (EPP) drew a 13 February 2026 first-cycle CRL: FDA agreed PPIX fell, but saw no association with sunlight-exposure endpoints — a rare-disease surrogate rejection, and not a refile (Disc Medicine PR, 13 Feb 2026).
  • REGENXBIO RGX-121 (Hunter / MPS II) CRL was 7 February 2026 (first-cycle accelerated-approval package; natural-history / biomarker), already in the basket as a lateral risk, not a new post-Agios refile reject (REGENXBIO PR via PR Newswire, 9 Feb 2026).
  • REPL's April 2026 CRL was overcome by the August approval.

Falsifier remains live, not triggered. Capricor's 9–3 vote is the closest Diamantes-era not-lenient public signal; it did not close as a rejection.

CRL transparency since April 2026 — paused, then partially resumed (not still walked back)

The chain's "no CRLs released since April; Covington & Burling citizen petition" is directionally right on the pause, stale on the aftermath. Covington filed FDA-2026-P-4369 on behalf of an unnamed company asking for pre-disclosure notice / redaction process (Regulations.gov FDA-2026-P-4369-0001). Trade press reported an April pause, then a July resume of publication. This pass fetched the live openFDA transparency API: 458 records, last_updated 2026-08-13, newest returned letter ITM Solucin GmbH, 7 August 2026, NDA 218705, Complete Response, Unapproved (https://api.fda.gov/transparency/crl.json). So the information edge is not "still fully walked back"; it is on-again / off-again, with letters dated after the April pause now in the public set. Formal rulemaking (RIN 0910-AJ16) remains the unresolved legal layer (secondary; not fetched as a proposed-rule HTML this pass).

Contradictions and open questions

  • Lenient vs erratic, same week: REPL approved over a review-team non-recommend after 10–3; Capricor 9–3 against cardiomyopathy, then three-month deferral. That is exactly the Herper "decimated / get it right" risk, not a clean "open for business" monotone.
  • Step 1 still has n=1 missed-endpoint acceptance (Agios) and n=0 missed-endpoint approvals. FAYUVI and TUDRIQEV are real approvals; they fail the missed-endpoint rare-disease test.
  • Schmidt "no ADCOM" remains unverified. Calendar absence ≠ company confirmation.
  • Will Capricor's 22 Nov 2026 PDUFA (refined upper-limb indication) be approve, CRL, or another slip? That is the next rare-disease litmus.
  • Will Agios's 1 Nov 2026 PDUFA convert acceptance into approval — or a surprise ADCOM / CRL? Until then, do not file approved-despite-missed-VOC.
  • CRL database cadence after 13 Aug is unknown (API snapshot frozen that day). Whether real-time posting is durable vs another pause is still open.

Provenance

Rounds run: 3 of 3 (full). No early exit.

Sub-questions by round:

Round 1 (broad survey):

  1. Agios mitapivat SCD sNDA: PDUFA still 1 Nov 2026? Priority Review / not approved? ADCOM scheduled? REIGNITE recruiting?
  2. Replimune RP1 30 Jul 2026 ADCOM outcome and subsequent FDA action
  3. Capricor 30 Jul 2026 ADCOM outcome and subsequent FDA action
  4. Dyne late-January PDUFA — decided?
  5. Second missed-endpoint rare-disease APPROVAL, or high-profile refile CRL / CRL-transparency walk-back

Round 2 (drill-down):

  1. Post-July Agios paper (Q2 8-K / EDGAR) — targeting whether PDUFA or ADCOM language moved
  2. Capricor post-ADCOM action (approve / CRL / defer) — targeting the open Jul 30 litmus
  3. Ultragenyx UX111 / other rare-disease approvals — targeting the "second missed-endpoint approval" test
  4. openFDA CRL corpus after April — targeting whether transparency is still walked back

Round 3 (resolve remaining uncertainty):

  1. Official FDA letters (TUDRIQEV, FAYUVI, SBRA) vs IR 403s — targeting primary-document confirmation of approve / CMC-vs-efficacy
  2. Disc / RGNX CRLs — targeting whether any high-profile reject fires the step-1 falsifier
  3. DYN EDGAR after 20 Jul — targeting "decided or not"

Anchor source (Grokipedia): skipped per brief ("No encyclopedia-as-source").

X sources: not requested (--include-x off).

URLs fetched (successful vs failed):

Round 1:

Round 2:

Round 3:

Tools used: WebSearch, WebFetch (mostly timeout), curl with browser/SEC UA, ClinicalTrials.gov v2 API, openFDA API, SEC EDGAR / data.sec.gov. grokipedia-fetch skipped. x-fetch skipped. Generated: 2026-09-19 21:30 UTC

Referenced by